Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 12 of the 31 sources its claims cite were checked for support.

Maintenance or Discontinuation of Antidepressants in Primary Care

Open access

Abstract

BACKGROUND Patients with depression who are treated in primary care practices may receive antidepressants for prolonged periods. Data are limited on the effects of maintaining or discontinuing antidepressant therapy in this setting. METHODS We conducted a randomized, double-blind trial involving adults who were being treated in 150 general practices in the United Kingdom. All the patients had a history of at least two depressive episodes or had been taking antidepressants for 2 years or longer and felt well enough to consider stopping antidepressants. Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their current antidepressant therapy (maintenance group) or to taper and discontinue such therapy with the use of matching placebo (discontinuation group). The primary outcome was the first relapse of depression during the 52-week trial period, as evaluated in a time-to-event analysis. Secondary outcomes were depressive and anxiety symptoms, physical and withdrawal symptoms, quality of life, time to stopping an antidepressant or placebo, and global mood ratings. RESULTS A total of 1466 patients underwent screening. Of these patients, 478 were enrolled in the trial (238 in the maintenance group and 240 in the discontinuation group). The average age of the patients was 54 years; 73% were women. Adherence to the trial assignment was 70% in the maintenance group and 52% in the discontinuation group. By 52 we…

Overview

CoChat Summary

TL;DR

In primary care patients who felt well enough to stop long-term antidepressants, tapering to placebo led to a higher risk of depression relapse by 52 weeks than continuing maintenance therapy. Discontinuation was also associated with more depressive, anxiety, and withdrawal symptoms, though serious adverse events were similar between groups.

Key findings

  • Relapse of depression by 52 weeks occurred in 92 of 238 patients (39%) in the maintenance group and 135 of 240 (56%) in the discontinuation group (hazard ratio, 2.06; 95% CI, 1.56 to 2.70; P<0.001).
  • At 12 weeks, the discontinuation group had worse depressive symptoms (PHQ-9 mean, 4.1 vs. 6.3; difference, 2.2 points; 95% CI, 1.5 to 2.8), anxiety symptoms (GAD-7 mean, 3.1 vs. 5.3; difference, 2.4 points; 95% CI, 1.8 to 3.0), withdrawal symptoms (modified DESS mean, 1.3 vs. 3.1; difference, 1.9 points; 95% CI, 1.5 to 2.3), and mental health–related quality of life (SF-12 mental component mean, 46 vs. 41; difference, −4.9 points; 95% CI, −6.4 to −3.3).
  • More patients in the discontinuation group stopped trial medication (48% vs. 30%; hazard ratio, 2.28; 95% CI, 1.68 to 3.08) and returned to an antidepressant prescribed by their primary care doctor (39% vs. 20%).
  • Serious adverse events were similar: 9 (4%) in the maintenance group and 8 (3%) in the discontinuation group; there were no deaths or suicide attempts during the trial.

Methods

  • Multicenter, randomized, double-blind trial in 150 general practices across four sites in England; adults aged 18 to 74 years were eligible if they had at least two prior depressive episodes or had taken antidepressants for more than 2 years, had been taking standard doses of citalopram, sertraline, fluoxetine, or mirtazapine for at least 9 months, had recovered from their most recent depressive episode, and felt well enough to consider stopping. Current ICD-10 depression was the main exclusion criterion.
  • A total of 1466 patients underwent screening; 478 were enrolled and randomly assigned 1:1 to maintain current antidepressant therapy (n=238) or taper and discontinue with matching placebo (n=240), with 52-week follow-up.
  • The primary outcome was first relapse of depression during 52 weeks, analyzed in a time-to-event analysis with Cox proportional-hazards modeling adjusted for baseline CIS-R depression score; secondary outcomes included PHQ-9, GAD-7, Toronto Side Effect Scale, modified DESS, SF-12, time to stopping medication, and global mood ratings.

Limitations

  • The paper states that it investigated only three SSRIs with similar pharmacologic profiles plus mirtazapine, so findings cannot be generalized to other antidepressant classes; it excluded escitalopram and nonstandard doses; only a small percentage of invited patients participated, which may have introduced bias; findings pertain only to patients who felt ready to discontinue; the relapse measure was adapted and required retrospective assessment over 12 weeks; the population lacked ethnic diversity and was treated entirely in the U.K. health system, limiting generalizability; recall bias was possible; and detailed information about the original prescribing decision or diagnosis was unavailable.
  • The paper states that there was no prespecified adjustment for multiple comparisons for secondary outcomes, so no definite conclusions can be drawn from those data.
  • Evident from the text: adherence differed between groups (70% maintenance vs. 52% discontinuation), and 39% of the discontinuation group returned to antidepressants by the end of the trial, which may explain the lack of between-group differences at 52 weeks; 10 patients without timing of relapse were excluded from the primary analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2106356

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

5 Valid · 3 Not valid · 2 Not checked · 45 Own results and interpretations

18 more claims

Create a free account to see all 55 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 20
  • Probably not a substantial claim. 17
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 25 references

Cited by

See all 192

Metadata

Authors
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., Hunt, A., Pervin, J., & Lewis, G.
Affiliations
University of Bristol (GB)
Venue
New England Journal of Medicine
Published
2021-09-30
Volume
385
Issue
14
Pages
1257-1267
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3204219363
Cited by
192
References
25
Citations by year
2026: 33 · 2025: 42 · 2024: 44 · 2023: 35 · 2022: 27 · 2021: 10
FWCI
16.93
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Explore Bristol Research (publishedVersion, other-oa)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Liverpool John Moores University (acceptedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Bristol Research (University of Bristol) (submittedVersion, other-oa)
Funders
Health Technology Assessment Programme (13/115/48)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
antidepressant discontinuation, antidepressant tapering, depression relapse, long-term antidepressant use, citalopram, fluoxetine, sertraline, mirtazapine, withdrawal symptoms, primary care depression, quality of life
MeSH terms
Adult, Aged, Antidepressive Agents, Anxiety Disorders, Depressive Disorder, Double-Blind Method, Female, Follow-Up Studies, United Kingdom, Humans, Male, Middle Aged, Primary Health Care, Surveys and Questionnaires, Recurrence, Citalopram, Selective Serotonin Reuptake Inhibitors, Withholding Treatment, Kaplan-Meier Estimate, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maintenance or Discontinuation of Antidepressants in Primary Care. https://app.cochat.ai/papers/10.1056/nejmoa2106356
The paper
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., Lanham, P., Moore, M., Nazareth, I., Wiles, N., Bacon, F., Bird, M., Brabyn, S., Burns, A., Clarke, C. S., . . . Lewis, G. (2021). Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2106356

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.